Vimarsana
Biggest News Aggregation in the World

Page 35 - Platform Technology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Platform Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Platform Technology Today - Breaking & Trending Today

A Closer Look at Sinoveda's Technology for Developing Combination Drugs - Vimarsana News

A Closer Look at Sinoveda's Technology for Developing Combination Drugs

/PRNewswire/ -- The health world is often divided between powerfully precise synthetic Western drugs and ancient, often-inconsistent natural Eastern medicinal...

Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD - Vimarsana News

Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and DurationKANSAS CITY, Kan., July 11, 2023 -- Cingulate Inc. , a biopharmaceutical company utilizing its...

GBGA confirms departure of CEO Foster - Vimarsana News

GBGA confirms departure of CEO Foster

The Gibraltar Betting and Gaming Association (GBGA) has announced that Paul Foster has resigned as its chief executive.

Lonza Group AG: Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering - Vimarsana News

Lonza Group AG: Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering

Lonza Group AG / Key word(s): Acquisition/Mergers & Acquisitions Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering 01.06.2023 / 07:00 CET/CEST Lonza to acquire

Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update - Vimarsana News

Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update

Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 -- Vaccinex,... | May 15, 2023